# Hemodialysis Access Blood Flow and Cardiopulmonary Outcomes

**Authors:** Zahidul Mondal, Mojgan Jalalzadeh, Steve Khalil

PMC · DOI: 10.7759/cureus.98259 · Cureus · 2025-12-01

## TL;DR

High blood flow from hemodialysis access can lead to heart and lung complications, and monitoring and managing this flow is crucial for patient outcomes.

## Contribution

This paper identifies a critical blood flow threshold and outlines a clinical framework for managing hemodialysis access complications.

## Key findings

- AV access flow exceeding 1.5-2.0 L/min is strongly linked to left-ventricular hypertrophy, high-output heart failure, and pulmonary hypertension.
- Combining duplex ultrasonography, ultrasound dilution, and echocardiography improves diagnostic accuracy for hemodynamic complications.
- Individualized access planning within the ESRD Life-Plan framework helps prevent irreversible cardiopulmonary damage.

## Abstract

Arteriovenous (AV) access remains the cornerstone of long-term hemodialysis, yet it profoundly alters systemic hemodynamics. The resulting increase in venous return and cardiac output is initially adaptive but, when excessive, can precipitate maladaptive cardiovascular remodeling and downstream complications. A comprehensive literature search was performed using PubMed, Scopus, and Embase databases for studies published between 2018 and 2025. The search terms included arteriovenous fistula, hemodialysis, high-output heart failure, pulmonary hypertension, and left-ventricular hypertrophy (LVH). Due to the heterogeneity in design and the limited availability of randomized data, this paper was developed as a narrative synthesis rather than a formal systematic review. Arteriovenous access flow exceeding 1.5-2.0 L/min, a threshold that indicates excessive flow, or representing more than 25-30% of cardiac output, is strongly associated with an increased risk of left-ventricular hypertrophy (LVH), high-output heart failure (HOHF), and pulmonary hypertension (PH). This threshold serves as a crucial clinical marker, guiding the diagnosis and management of high-flow AV access complications. Diagnostic assessment should combine duplex ultrasonography, ultrasound dilution techniques, and echocardiography. Right-heart catheterization, a procedure that involves inserting a catheter into the right side of the heart to measure pressures and oxygen levels, is used to confirm the hemodynamic burden. Optimal management involves meticulous volume control, targeted pharmacologic therapy, and, when indicated, surgical or endovascular flow reduction. Arteriovenous access remains both a therapeutic necessity and a potential hemodynamic stressor. Consistent flow surveillance, periodic echocardiographic evaluation, and individualized access planning within the ESRD Life-Plan framework, a patient-centered care model that aligns access strategy with clinical status, lifestyle, and preferences, are essential for preventing irreversible cardiopulmonary remodeling and optimizing long-term clinical outcomes.

## Linked entities

- **Diseases:** high-output heart failure (MONDO:0005253), pulmonary hypertension (MONDO:0005149)

## Full-text entities

- **Diseases:** LVH (MESH:D017379), ESRD (MESH:D007676), PH (MESH:D006976), HOHF (MESH:D006333), arteriovenous fistula (MESH:D001164)
- **Chemicals:** oxygen (MESH:D010100)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12755889/full.md

## References

37 references — full list in the complete paper: https://tomesphere.com/paper/PMC12755889/full.md

---
Source: https://tomesphere.com/paper/PMC12755889